TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Yuan, Bao Zhu ^a,b   Chapman, Joshua ^b   Ding, Min ^b   Wang, Junzhi ^a   Jiang, Binghua ^c   Rojanasakul, Yon ^c   Reynolds, Steven H ^b  

^a NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Akt; Apoptosis; Malignant pleural mesothelioma; Mcl 1; Proteasome inhibitor; Trail

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CASPASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN MCL 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; MCL1 PROTEIN, HUMAN; MESSENGER RNA; MYELOID LEUKEMIA FACTOR 1; PROTEASOME INHIBITOR; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN NCI H2052; CELL STRAIN NCI H2452; CELL STRAIN NCI H28; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MESOTHELIUM CELL; PLEURA MESOTHELIOMA; POSITIVE FEEDBACK; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PLEURAL NEOPLASMS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PLEURAL NEOPLASMS; PROTEASOME INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84875165367     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-140     Document Type: Article

References (41)

1. Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol 1981, 8:313-320.
2. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997, 145:211-218.
3. Goudar RK. New therapeutic options for mesothelioma. Curr Oncol Rep 2005, 7:260-265.
4. Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 2005, 19:1117-1136. vii.
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
6. Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005, 11:2300-2304.
7. Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, Lardinois D, Betticher D, Schmid R, Stupp R. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007, 18:1196-1202. Epub 2007 Apr 1111.
8. Bolukbas S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with Cisplatin/Permetrexed and radiotherapy. Lung Cancer 2009, 74:75-85.
9. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001, 11:S22-S26.
10. Cryns V, Yuan J. Proteases to die for. Genes Dev 1998, 12:1551-1570.
11. Green DR. At the gates of death. Cancer Cell 2006, 9:328-330.
12. Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem 2004, 73:87-106.
13. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607.
14. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
15. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
16. Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, Moch H, Weder W. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008, 33:502-506.
17. Aldieri E, Orecchia S, Ghigo D, Bergandi L, Riganti C, Fubini B, Betta PG, Bosia A. Simian virus 40 infection down-regulates the expression of nitric oxide synthase in human mesothelial cells. Cancer Res 2004, 64:4082-4084.
18. Carbone M, Pass HI, Miele L, Bocchetta M. New developments about the association of SV40 with human mesothelioma. Oncogene 2003, 22:5173-5180.
19. Pass HI, Donington JS, Wu P, Rizzo P, Nishimura M, Kennedy R, Carbone M. Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences. J Thorac Cardiovasc Surg 1998, 116:854-859.
20. Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, Mutti L, Gaudino G. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 2005, 65:5256-5262.
21. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421.
22. Henderson CJ, Aleo E, Fontanini A, Maestro R, Paroni G, Brancolini C. Caspase activation and apoptosis in response to proteasome inhibitors. Cell Death Differ 2005, 12:1240-1254.
23. Yuan B, Chapman J, Reynolds SH. Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage. Oncogene 2009, 28:3775-3786.
24. Yuan B-Z, Chapman JA, Reynolds SH. Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells. Translational Oncology 2008, 1:129-140.
25. Finnberg N, El-Deiry WS. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle 2008, 7:1525-1528.
26. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008, 8:782-798.
27. Sayers TJ, Murphy WJ. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 2006, 55:76-84.
28. Das T, Sa G, Sinha P, Ray PK. Induction of cell proliferation and apoptosis: dependence on the dose of the inducer. Biochem Biophys Res Commun 1999, 260:105-110.
29. Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, McCormick F, Feng J, Tsichlis P. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998, 17:313-325.
30. Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC, Reynolds SH. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 2004, 23:1405-1411.
31. Yuan BZ, Jefferson AM, Millecchia L, Popescu NC, Reynolds SH. Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. Exp Cell Res 2007, 313:3868-3880.
32. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002, 8:945-954.
33. Galetic I, Andjelkovic M, Meier R, Brodbeck D, Park J, Hemmings BA. Mechanism of protein kinase B activation by insulin/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase-significance for diabetes and cancer. Pharmacol Ther 1999, 82:409-425.
34. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, Wang X. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003, 17:1475-1486.
35. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005, 121:1085-1095.
36. Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 2005, 280:10491-10500.
37. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008, 11:32-50.
38. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005, 19:1294-1305.
39. Franke TF, Cantley LC. Apoptosis. A Bad kinase makes good. Nature 1997, 390:116-117.
40. He YY, Huang JL, Gentry JB. Chignell. Epidermal growth factor receptor down-regulation induced by UVA in human keratinocytes does not require the receptor kinase activity. J Biol Chem 2003, 278:42457-42465.
41. Pinton G, Manente AG, Angeli G, Mutti L, Moro L. Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axix in malignant pleural mesothelioma. PloS One 2012, 7:1-7.